Mucosal fungal dysbiosis is associated with early postoperative endoscopic recurrence after bowel resection for Crohn’s disease
International Journal of Colorectal Disease · 2026
DOI: 10.1007/s00384-025-05070-x ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2026. Verfasst von Liangdong Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Crohn Disease, Dysbiosis, Intestinal Mucosa, Fungi. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: Anastomotic recurrence after ileocolectomy for Crohn's disease may be related to the gut microbiota, but the role of mycobiota remains unclear. This study aimed to investigate associations between mucosal mycobiota at resection and early postoperative endoscopic recurrence, and assess their predictive potential. METHODS: We recruited 55 Crohn's disease patients undergoing bowel resection (October 2022-February 2024) with one-year endoscopic follow-up. Mucosal samples obtained during surgery underwent fungal internal transcribed spacer 1 sequencing to characterize the fungal communities. Multivariate analysis identified risk factors for early postoperative endoscopic recurrence. Predictive model performance was evaluated using receiver operating characteristic curve analysis. RESULTS: Twenty patients (36.4%) developed early postoperative endoscopic recurrence and were assigned to the recurrence group. Multivariate analysis identified preoperative low serum albumin level and elevated postoperative neutrophil-to-lymphocyte ratio as independent risk factors. The recurrence group exhibited an increased relative abundance of Basidiomycota, an elevated Basidiomycota/Ascomycota ratio, and heightened relative abundances of Malassezia restricta and Debaryomyces hansenii. A combined predictive model integrating three potential fungal biomarkers demonstrated superior predictive performance for early postoperative endoscopic recurrence. CONCLUSION: Early postoperative endoscopic recurrence in Crohn's disease is significantly associated with mucosal fungal dysbiosis during bowel resection. Integrating mycobial factors can more effectively predict early postoperative endoscopic recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Anorectal Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, China.
- Department of General Surgery, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of General Surgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. gongjianfeng@nju.edu.cn.
Zitieren
APA
Zheng, L., Zhao, L., Zhang, J., Zhu, F., Li, S., Yu, Z., Zhang, T., & Gong, J. (2026). Mucosal fungal dysbiosis is associated with early postoperative endoscopic recurrence after bowel resection for Crohn’s disease. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-025-05070-x
Vancouver
Zheng L, Zhao L, Zhang J, Zhu F, Li S, Yu Z, et al. Mucosal fungal dysbiosis is associated with early postoperative endoscopic recurrence after bowel resection for Crohn’s disease. International Journal of Colorectal Disease. 2026. doi:10.1007/s00384-025-05070-x
BibTeX
@article{Zheng2026,
author = {Zheng, Liangdong and Zhao, Lei and Zhang, Jie and Zhu, Feng and Li, Song and Yu, Zeqian and Zhang, Tenghui and Gong, Jianfeng},
title = {Mucosal fungal dysbiosis is associated with early postoperative endoscopic recurrence after bowel resection for Crohn’s disease},
journal = {International Journal of Colorectal Disease},
year = {2026},
doi = {10.1007/s00384-025-05070-x}
}
EUVIMED